Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections
November 26, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, is pleased to announce that the first two patients in the second cohort of its ongoing proof-of-concept clinical trial for BSG005 has successfully begun treatment with BSG005. The patients are suffering from a severe infection caused by Aspergillus and Mucor Mycosis respectively. These two patients represent challenging cases where current antifungal treatments have proven ineffective due to resistance and renal impairment.
“It is exciting to advance to this next stage of dosing with BSG005,” said Tine Olesen, CEO of Biosergen. “For patients with no effective options, BSG005 has the potential to be lifesaving, especially if the promising safety and efficacy results from the first cohort continue. As we progress through dose escalation, we hope to continue to observe no severe side effects, allowing us to gain deeper insights into BSG005’s potential for patients in critical need.”
Following positive safety and efficacy results from the first cohort, the trial’s independent Data Safety Review Committee approved progression to higher dosing in this second cohort. This phase initiates patient treatment at 0.8 mg/kg per day, with potential escalation up to 1.5 mg/kg depending on patient response and safety.
The second cohort will include up to five patients and is performed in collaboration with Biosergen’s partners in India, as with the first cohort. Biosergen aims to develop BSG005 as a new standard for treating invasive fungal infections in patients who are resistant to existing treatments or are ineligible for such treatment due to kidney impairment.
For further information, please contact:
Tine Kold Olesen, CEO
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net
Niels Laursen, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net
The Company's Certified Advisor is Carnegie Investment Bank AB (publ)
ABOUT BIOSERGEN
Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year.